Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T16:13:05.601Z.
Calculation as of: 2026-10-06T16:13:05.601Z.
Quote observation: 2026-10-05T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
MiniMed Group, Inc.
Market Cap
$560.00M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$547.18M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$566.38M
Operating Cash Flow Yield
44.83%
TTM Avg
19.98%
3Y Avg
17.70%
5Y Avg
17.70%
Market Cap
$568.20M
Operating Cash Flow Yield
N/A
TTM Avg
4.06%
3Y Avg
4.43%
5Y Avg
13.92%
Market Cap
$550.11M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$552.40M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$574.01M
Operating Cash Flow Yield
N/A
TTM Avg
8.85%
3Y Avg
8.85%
5Y Avg
8.85%
Market Cap
$542.17M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$540.26M
Operating Cash Flow Yield
3.63%
TTM Avg
3.98%
3Y Avg
3.57%
5Y Avg
3.57%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiniMed Group, Inc. (MMEDV) | $560.00M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $547.18M | N/A | N/A | N/A | N/A |
| CorMedix Inc. (CRMD)vs › | $566.38M | 44.83% | 19.98% | 17.70% | 17.70% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $568.20M | N/A | 4.06% | 4.43% | 13.92% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $550.11M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $552.40M | N/A | N/A | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $574.01M | N/A | 8.85% | 8.85% | 8.85% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $542.17M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $540.26M | 3.63% | 3.98% | 3.57% | 3.57% |
| ProKidney Corp. (PROK)vs › | $536.32M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
